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Objective: Approximately 30% of schizophrenia patients fail to respond to antipsychotic therapy 
and are classified as having treatment resistant-schizophrenia (TRS). Clozapine is the most 
efficacious drug for TRS and may deliver its superior therapeutic effects partly by modulating 
glutamate neurotransmission. Response to clozapine is highly variable and may depend on 
genetic factors as indicated by twin studies. We investigated eight polymorphisms in the N-
methyl-D-aspartate glutamate receptor (NMDAR) subunit gene GRIN2B with response to 
clozapine. Methods: GRIN2B variants were genotyped using standard TaqMan procedures in 171 
European schizophrenia patients deemed resistant or intolerant to treatment. Response was 
assessed using change in Brief Psychiatric Rating Scale (BPRS) scores following six months of 
clozapine therapy. Categorical and continuous response was assessed using Chi-square test and 
analysis of covariance (ANCOVA), respectively.  Results: No associations were observed 
between the variants and response to clozapine. A-allele carriers of rs1072388 responded 
marginally better to clozapine therapy than GG-homozygotes, however the difference was not 
statistically significant (p=0.067, uncorrected). Conclusions: Our findings do not support a role 
for these GRIN2B variants in altering response to clozapine in our sample. Investigation of 










Treatment resistant schizophrenia (TRS) occurs in approximately 30% (20-40%) of patients treated with 
antipsychotic (AP) drugs (Borgio et al. 2007, Elkis & Meltzer 2007, Solanki, Singh & Munshi 2009). 
TRS patients experience suboptimal response characterized by persistent positive symptoms that often 
result in long periods of hospitalization (McGlashan 1988) and chronic severe disability. Treatment 
resistance remains an immense burden to both patients and their families and is associated with annual 
healthcare costs ranging 3 to 11 times higher than schizophrenia (SCZ) patients who respond to treatment 
($66,360-$163,795 vs. $15,500-$22,300 per year). TRS is also associated with poorer quality of life that 
is approximately 20% lower than patients with SCZ who achieve remission (0.61 vs. 0.75) (Kennedy et 
al. 2014).  
The atypical AP drug clozapine (CLZ) is particularly effective for treating the persistent symptoms 
experienced by patients with TRS. A landmark clinical trial conducted by Kane et al. showed that 
approximately 30% of TRS patients responded to CLZ versus only 4% of patients given the prototypical 
AP chlorpromazine (CPZ) (p<0.001) (Kane et al. 1988). As an atypical AP, CLZ differs from typical APs 
in particular dimensions, such as decreased dopamine (D2) receptor affinity (Altar et al. 1986) and 
lowered risk for adverse effects such as extrapyramidal symptoms (EPS) and tardive dyskinesia (TD) 
(Pickar et al. 1992, Tandon & Fleischhacker 2005). CLZ also has the unique ability to alter other 
neurotransmitter systems such as serotonin and glutamate (reviewed in Miyamoto et al. 2005).  
A great deal of evidence suggests CLZ augments glutamate neurotransmission (reviewed in Heresco-
Levy 2003). One pillar supporting this theory stems from observations that CLZ is capable of blunting the 
psychoto-mimetic effects of glutamate antagonists in SCZ patients (Malhotra et al. 1997). These 
antagonists, such as phencyclidine (PCP) and ketamine, bind to the glutamate N-methyl-D-aspartate 
receptor (NMDAR) and have been observed to elicit schizophrenia-like symptoms in healthy controls and 
exacerbate psychotic symptoms in SCZ patients (Luby et al. 1959, Luisada 1978, Javitt & Zukin 1991, 
Lahti et al. 2001) – observations that form the basis of the “glutamate hypo-function hypothesis” of SCZ. 
Collectively, these findings suggest that blockade and underactivity of glutamate signaling contributes to 
clinical presentation of SCZ and that CLZ is able to offer therapeutic relief in part by augmenting 
glutamatergic signals.  
Findings from preclinical models and functional studies also support this theory. CLZ administration 
reverses PCP-induced psychosis-like behavior such as hyper-locomotion  (Freed, Bing & Wyatt 1984, 
Sun, Hu & Li 2009, Zhao, Sun & Li 2012), social deficits (Corbett et al. 1995), enhanced immobility 
(Noda et al. 1995) and pre-pulse inhibition (PPI) deficits (Linn et al. 2003). Functional studies in both 
preclinical models and SCZ patients observe that CLZ alters glutamate receptor subunit expression 
(Fitzgerald et al. 1995, Meshul et al. 1996), binding (Giardino et al. 1997, Pilowsky et al. 2006), and 
density (Ossowska et al. 1999, Schmitt et al. 2003). CLZ also appears to alter glutamate concentrations 
and activate excitatory glutamate neurotransmission in different brain regions as exhibited by: micro-
dialysis studies in rodents (Daly & Moghaddam 1993, Yamamoto & Cooperman 1994), increased 
amplitude of excitatory post-synaptic potentials (EPSPs) in neuronal cell cultures (Kubota et al. 2000, 
Banerjee et al. 1995, Arvanov et al. 1997, Ninan, Jardemark & Wang 2003, Kargieman et al. 2007), and 
increased serum glutamate levels in patients switched to CLZ (Evins et al. 1997). Taken together, these 
results provide evidence for CLZ’s ability to alter glutamate signaling – a factor that may distinguish CLZ 
as the most efficacious drug for treatment resistant patients.  
Clinical response to CLZ is highly variable (Bleehen 1993, Davis, Chen & Glick 2003) and an estimated 
30-60% of TRS patients fail to respond to CLZ therapy {{336 Kane,J. 1988; 378 Lieberman,J.A. 1994}}.  
Because early intervention strategies with AP drugs attenuates disease prognosis, the ability to predict 
response prior to drug administration would have important clinical utility (Gunduz-Bruce et al. 2005, 
Perkins et al. 2005, Emsley et al. 2007, Wyatt & Henter 2001). A portion of the inter-individual 
variability in CLZ response is thought to be caused by genetic variation  (Mata et al. 2001, Horacek et al. 
2001, Theisen et al. 2005, Hoyer et al. 2010, Vojvoda et al. 1996). Quite a few pharmacogenetic (PGx) 
studies investigating genetic variability and CLZ response have been conducted to date (reviewed in 
Kohlrausch 2013), however, no predictive test for AP response utilizing this genetic information is 
currently used in the clinic. The most notable gene variants investigated for association with CLZ 
response include those related to the dopamine, serotonin and to a lesser degree, glutamate 
neurotransmitter systems. 
Glutamate is becoming increasingly popular in recent years due to novel SCZ therapies that target this 
neurotransmitter system (Heresco-Levy et al. 1996, Pinard et al. 2010, Hopkins 2011, Patil et al. 2007). 
Additional advancements in SCZ genetics have also yielded promising genome-wide (GWAS) hits for 
glutamate genes in risk (GAIN Collaborative Research Group et al. 2007, Jia et al. 2012, Schizophrenia 
Working Group of the Psychiatric Genomics Consortium 2014). Genome-wide significant associations 
with schizophrenia were observed in the glutamate system genes GRM3, GRIN2A, GRIA1, and GRIN2B. 
The GRIN2B gene (138252 [MIM]) codes for subunit 2B of the NMDAR and is of particular interest. 
This gene contains 13 exons and is mapped to 12p12 (Mandich et al. 1994, Endele et al. 2010). Single 
nucleotide polymorphisms (SNPs) in GRIN2B have been investigated for association with several 
neuropsychiatric disorders, including drug response phenotypes (Table 1). A small number of GRIN2B 
variants have also been studied in CLZ response – while no associations between rs1806201 (2664C/T) 
(Hong et al. 2001, Chiu et al. 2003) or rs1019385 (-200T/G) (Hwang et al. 2011) were observed, the 
rs1805502 variant (T5988C) predicted negative symptom response during CLZ therapy (Martucci & 
Kennedy 2010). Associations between additional GRIN2B polymorphisms and CLZ response have not yet 
been investigated. This study examined for associations between eight GRIN2B variants and response to 
CLZ monotherapy in a sample of treatment resistant or intolerant patients.  
METHODS 
Subjects 
One hundred and seventy-five patients meeting Diagnostic and Statistical Manual of Mental Disorders 
(DSM)-III-R or DSM-IV criteria for schizophrenia or schizoaffective disorder were included in this study 
(American Psychiatric Association 1987, American Psychiatric Association 1994). Patients were recruited 
from three clinical sites: Case Western Reserve University in Cleveland, Ohio (HY Meltzer, n=74), 
Hillside Hospital in Glen Oaks, New York (JA Lieberman, n=73), and the University of California 
at Irvine (SG Potkin, n=28). All patients were considered European based on self-reported ancestry. 
Informed consent was obtained from each participant prior to study enrollment in accordance with the 
Ethical Principles for Medical Research Involving Human Subjects at the Centre for Addiction and 
Mental Health (CAMH) and with the Helsinki Declaration of 1975, as revised in 1989 (World Medical 
Association 2013). 
The majority of patients met criteria for TRS defined as failure to respond to two or more AP drug trials 
in the previous five years (involving drugs from two different chemical classes, with doses ≥1000mg 
chlorpromazine equivalents for four to six weeks), accompanied by no period of good functioning within 
the preceding five years (Kane et al. 1988). The remaining participants (<15%) met criteria for treatment 
intolerance defined as the presence of moderate to severe TD and/or extreme EPS making treatment with 
therapeutic dosages intolerable (Lieberman et al. 1994). Before beginning CLZ treatment, patients 
underwent a two to four week wash-out period which involved no administration of pharmacotherapy 
unless clinically necessary. Following the washout period, all patients were treated with CLZ 
monotherapy, with mean dosages of 453 mg/d, for a period of six months or longer. Benzodiazepines 
were administered intermittently during the titration period. Throughout treatment, CLZ serum levels 
were monitored to ascertain adherence to the medication.  
Response Measures  
Baseline Brief Psychiatric Rating Scale (BPRS) (Overall & Gorham 1962) scores were obtained at time 
of study enrollment I would recommend adding references that support that BPRS is a reliable rating 
method for treatment outcome in psychotic patients. Following CLZ administration, response was 
evaluated after six months using two BPRS scoring methods. The first was a categorical responder/non-
responder response measure that classified responders as individuals who experienced a ≥20% decrease in 
BPRS total score. The second scoring method was a quantitative response measure that divided the BPRS 
items into three subcategories [positive (BPOS), negative (BNEG), and general (BPRS)], and calculated 
the percent score reduction using the following equation: [(6 month score - baseline score)/(baseline 
score)] x 100.  
SNP Selection  
A literature search was conducted on PUBMED for the following terms: “GRIN2B”, “NMDAR”, “N-
methyl-D-aspartate receptor”, “clozapine” and “pharmacogenetics.” Literature pertaining to genetic 
association studies in psychiatric disorders and psychotropic drug response was reviewed to identify 
GRIN2B SNPs of interest.  Variants previously investigated for an association with CLZ response or other 
psychiatric phenotypes were considered for inclusion in our study.  Altogether, eight polymorphisms were 
selected: rs1072388, rs12826365, rs1806191, rs2284411, rs3764030, rs7301328 (366G>C), rs1806201 
(2664C>T), and rs890 (Table 1). These eight variants were assessed for potential functionality using the 
National Institute of Environmental Health Sciences (NIEHS) Functional SNP Prediction (FuncPred) 
database (Xu & Taylor 2009). Variants were deemed functional if alternate alleles were thought to have 
differential effects on gene transcription, translation, or splicing.  
Variant rs1072388 and rs12826365 were selected from the Genetics Association Information Network 
(GAIN) schizophrenia Genome Wide Association Study (GWAS) as lowest p-value GRIN2B SNPs from 
the European and African samples, respectively (Ayalew et al. 2012). Variant rs1806191 was previously 
investigated in SCZ risk and obsessive compulsive disorder (OCD) (Di Maria et al. 2004, Alonso et al. 
2012), while variant rs2284411 has been tested for associated with attention deficit hyperactivity disorder 
(ADHD) (Dorval et al. 2007, Park et al. 2013). The promoter variant rs3764030 has been previously 
studied in autism spectrum disorder (ASD) (Yoo et al. 2012) and may affect GRIN2B expression by 
altering transcription factor binding (TFBS). Both rs7301328 and rs1806201 have been investigated in a 
number of psychiatric phenotypes, including response to lithium ((Szczepankiewicz et al. 2009) and CLZ 
(Hong et al. 2001). These SNPs lie near intron-exon borders (within two base-pairs, specifically) and may 
regulate mRNA spicing. Lastly, rs890 has been investigated in SCZ risk (Di Maria et al. 2004), treatment-
resistant depression (TRD) (Zhang et al. 2014), CLZ-induced OCD (CI-OCD) (Cai et al. 2013), and 
response to lithium (Szczepankiewicz et al. 2009). This variant lies in a micro RNA (miRNA) binding 
site at the 3’ untranslated region (UTR) of GRIN2B and may alter translation initiation.  
DNA Isolation and Genotyping  
Venous blood samples were collected from study participants and sent to CAMH in Toronto, Canada 
where genomic DNA was isolated using the high salt method (Lahiri & Nurnberger 1991). GRIN2B 
genotypes were determined using TaqMan allele specific single tube assays, the ABI Prism®7500 
Sequence Detection System and the ABI allelic discrimination software according to the manufacturer’s 
instructions (Applied Biosystems, Foster City, CA, USA). The reaction mixture consisted of 20ng of 
genomic DNA, 2X TaqMan® Universal Master Mix and 40X SNP Genotyping Assay for a final reaction 
volume of 10 µL. The polymerase chain reaction (PCR) protocol consisted of a denaturation step for 10 
mins at 95oC, followed by 50 cycles of amplification that consisted of denaturation (92oC for 15 s) and 
annealing (60oC for 1 min). Genotype calls were confirmed by two independent researchers and 10% of 
the total sample was re-genotyped to ensure genotyping accuracy. Discordant genotypes were set as 
missing in the statistical analysis.  
Statistical Analyses 
Quality control (QC) was carried out using PLINK software v1.07 (Purcell et al. 2007). To pass filtering, 
SNPs were required to have a ≥90% genotyping rate and a minor allele frequency (MAF) of ≥0.05. 
Samples with a genotype success rate less than 75% across all markers (samples producing genotypes for 
5 SNPs or less) were also excluded from analysis. All statistical analyses were carried out using the 
Statistical Package for the Social Sciences (SPSS) v20 (IBM Corp, Armonk NY, USA) and PLINK 
software.  
Descriptive statistics were obtained for each clinical site. Mean age and baseline BPRS, BPOS, and 
BNEG subscale scores across sites were compared using Student’s t-test or analysis of variance 
(ANOVA), while frequency counts for gender and response rates were compared using Pearson’s Chi-
square test (χ2-test). Genotype and allele frequencies in the responder/non-responder (R/NR) groups were 
compared using χ2-test or Fisher’s exact test (for cell counts less than 5). Differences in percent score 
reduction in BPRS, BPOS, and BNEG subscales between genotype groups were compared using analysis 
of covariance (ANCOVA), co-varying for age and baseline scores.   
Hardy-Weinberg equilibrium (HWE) and linkage disequilibrium (LD) among SNPs were determined 
using Haploview v4.2 using the Solid Spine of LD to construct LD blocks  (Figure 2) (Barrett et al. 
2005). Haplotype analysis was carried out in UNPHASED v3.1.5 (Dudbridge 2008). Haplotypes with less 
than 5% frequency were removed from analysis. (Add a few sentences to clarify why a haplotype was 
constructed from only 3 SNPs 
Power calculations were conducted in Quanto v1.2.4 (Gauderman 2002, Gauderman & Morrison 2006). 
Correction for the effective number of independent markers was performed using the Nyholt method and 
resulted in a statistical significance threshold of p<0.0076 (Nyholt 2004).  
RESULTS 
Sample Characteristics 
Of the eight SNPs genotyped, seven met QC criteria and were included in subsequent association 
analyses. The genotype distribution for variant rs7301328 significantly deviated from HWE 
(p<0.05) and therefore this SNP was excluded from future analyses. The remaining SNPs had a mean 
genotyping rate of 99.1%. Regarding study participants, 18 patients were removed due to low genotyping 
efficiency (<75% of markers successfully genotyped). The remaining sample (n=157) had a mean 
genotyping efficiency of 98.9%. (Mention ppl were removed due to noncompliance?) 
Following QC, 157 European treatment resistant and intolerant patients were included in the study 
(Table 2). Our sample had over 80% power to detect an odds ratio (OR) as low as 2.00 (unmatched case-
control design: n=157, non-responder frequency=48.4%, MAF=30.5%, α/2=0.05) and down to 8.5% of 
the variance in the quantitative response variable (continuous design: n=85). The average minor allele 
frequency across the seven GRIN2B variants (excluding rs7301328) was used for power calculations. 
Patients between clinical sites did not differ in gender, categorical response rates, or BPRS/BPOS/BNEG 
baseline scores. The sites did, however, differ in mean age (F(2,157) =7.10, p=0.001). Post hoc analysis 
showed that the average age of the HY Meltzer sample was significantly lower than the SG Potkin 
sample. In order to combine samples for analysis, age and baseline BPRS/BPOS/BNEG scores were 
added as covariates to account for any disparities. Following QC, the final combined sample (n=157) 
consisted of 76.4% men and had a total mean age of 35.06 years (SD 8.1). Approximately half 
(51.6%) of the sample were considered CLZ “responders” (n=81). Quantitative response measures 
were available for a subset of patients in the BPRS (n=86), BPOS (n=84), and BNEG (n=85) subscales. 
GRIN2B SNP and Haplotype Association Analyses  
Genotype and allele frequencies for each of the seven GRIN2B variants were not significantly different 
between CLZ responder and non-responder groups or as measured by the quantitative percent score 
reduction in BPRS, BPOS, and BNEG subscales (Table 3). Variant rs1072388 A-allele carriers (AA and 
AG) responded marginally better to CLZ therapy than GG-homozygotes, however this difference was not 
statistically significant (puncorrected=0.067) (Figure 3). Haplotype association analyses confirmed allele and 
genotype findings with no association reported across all haplotypes tested (Table 4).  
2.5 DISCUSSION 
We report no significant associations among the seven GRIN2B variants analyzed and response to CLZ in 
our sample of patients. Despite A-allele carriers of the intronic variant rs1072388 responding marginally 
better to CLZ than G- homozygotes (puncorrected=0.067, genotype), this observation was statistically non-
significant (pcorrected=0.440, assuming 6.56 independent tests). The rs1806201 marker has previously 
been investigated in two other studies (Hong et al. 2001, Chiu et al. 2003). To our knowledge, this 
study is the first reported study to investigate associations of the remaining seven SNPs (rs1072388, 
rs3764030, rs12826365, rs2284411, rs1806191, rs890 and rs7301328) with CLZ response. Each 
aforementioned variant was selected because of previous investigation in CLZ response or other 
psychiatric phenotypes. After inclusion, the potential functionality of these variants was assessed using 
the NIEHS Functional SNP Prediction Database (Xu & Taylor 2009).  
Our negative finding for rs1806201 (2664C/T) is in accordance with previous reports that this variant is 
not associated with CLZ response (Hong et al. 2001, Chiu et al. 2003). These studies did report a 
marginally higher mean CLZ dosage for patients carrying the CC genotype of rs1806201. Due to the 
inter-individual variability in CLZ metabolism and absorption, future studies may benefit from measuring 
serum CLZ levels as opposed to dosage in order to predict response. An optimal threshold for CLZ serum 
levels has already been established (≥450 ng/mL) and may be of clinical utility to identify non-responders 
{{488 Potkin,S.G. 1994; 420 Lindenmayer,J. 1996}}.  
As a measure of genotyping quality, we tested for HWE to ensure genotype proportions observed in the 
study population coincided with those expected under equilibrium conditions (Hardy 1908, Weinberg 
1908). The potentially functional variant rs7301328 deviated from HWE (p<0.05, data not shown). This 
deviation may have been caused by a number of reasons including: systematic genotyping errors that 
mistype heterozygotes as homozygotes or vice versa (Gomes et al. 1999, Hosking et al. 2004), stochastic 
variation, or because of the study population’s biological characteristics. The biological explanation posits 
that patients deviate from HWE because of the effect an allele has on a disease phenotype, from which the 
sample was non-randomly selected (Xu & Taylor 2009, Wittke-Thompson, Pluzhnikov & Cox 2005). The 
cause for deviation from HWE in our sample appears to be genotyping error: no homozygous recessive 
genotypes were observed for either the rs7301328 responder or non-responder groups, even though this 
variant has a MAF of 23% and therefore, was expected to have a homozygous recessive count of 
approximately eight people out of 157. Because many genetic tests such as χ2-test require HWE to be 
assumed, rs7301328 was removed from subsequent analyses {{427 Sasieni,P.D. 1997}}. Retyping of 
rs7301328 with a newly designed assay remains a priority for future work. 
(Add a large paragraph or two discussing the importance of GRIN2B and glutamate in 
CLZ response). Mention physiological significance on the NMDAR, how its malfunction 
may correspond to the symptoms observed in patients w/ SCZ. Have to brainstorm for this 
section. Mention briefly GRM2&CLZ may be one proposed mechanism of action (See 
Thesis Discussion for this). Look online for papers on GRIN2B/NMDAR and CLZ.) (One 
done, transfer to thesis chapter) 
This study has several limitations. The sample size is relatively small and may not have had sufficient 
power to detect the effect sizes of these genes. To increase statistical power in the future, it will be 
necessary to collect larger CLZ response samples. One promising sample is being collected by the 
CRESTAR consortium in Europe (CRESTAR 2011). Sample heterogeneity may also have limited our 
findings. Patients were collected from three clinical sites that could have differed in methods and 
populations. Population ancestry was also based on self-report and in the future, a principle components 
analysis (PCA) on the study sample may provide more accurate ancestry profiles (Price et al. 2008, 
Paschou et al. 2008, Liu et al. 2011).  
Phenotypic heterogeneity regarding psychotic diagnosis between SCZ and SA disorder patients 
may have also increased variation in our sample. Several differences exist between SCZ and SA 
disorder. For instance, these disorders have different clinical presentations: SA disorder is 
characterized as  periods of psychosis with concurrent symptoms meeting criteria for a Major 
Mood Episode, while in comparison, SCZ is characterized by less frequent/prominent depressed or 
manic mood states {{288 American Psychiatric Association 2013}}. As well, SA disorder patients 
tend to experience higher rates of response and better clinical outcomes than patients with SCZ 
{{448 Harrow,M. 2000}}. Taken together, these differences suggest SCZ and SA disorder may differ 
in their underlying biology {{455 Abrams,D.J. 2008; 288 American Psychiatric Association 2013; 
449 Cosgrove,V.E. 2013}}. In regard to our findings, the propensity of SA disorder patients to 
respond more favourably to treatment may have increased our CLZ response rate, and it is 
possible that combining these two disorders into a single sample for analysis may have limited our 
ability to detect causal variants contributing to response. 
Inter-study variability may also limit comparison of results across investigations. We evaluated treatment 
response after six months of CLZ therapy, while previous studies evaluated response after shorter periods, 
e.g. two months of treatment (Hong et al. 2001, Chiu et al. 2003). Difference in treatment length is 
particularly problematic because response to CLZ may take five months or longer in a subset of patients 
(Lieberman et al. 1994, Meltzer & Okayli 1995) and thus patients deemed non-responders after a two 
month treatment period would have the potential to be reclassified as responders following a longer trial 
of CLZ therapy. This disparity makes comparing results across studies problematic. Consensus among 
duration of treatment would benefit researchers and make meta-analyses more efficient in the future.  
(Add paragraph on noncompliance, and the benefits of blood monitoring for patients 
taking CLZ). See Thesis Discussion. Incomplete outcome data 
(Add a paragraph highlighting the importance of multiple gene systems (ie 
glutamate/serotonin interaction) 
Environmental factors (diet, stress) on the complexity/variability in PGx studies). See 
Thesis Discussion. In addition, two environmental factors with the potential to alter CLZ 
metabolism were not controlled in our study: cigarette smoking and caffeine consumption. 
Cigarette smoking induces the Cytochrome P450 hepatic enzyme CYP1A2 that is primarily 
responsible for CLZ metabolism {{437 Bertilsson,L. 1994; 438 Ghassabian,S. 2010}}. As a result, 
smokers are observed to have lower CLZ serum levels than non-smokers {{436 Seppala,N.H. 1999; 
435 Palego,L. 2002}} and therefore require higher CLZ dosages to achieve similar plasma levels as 
patient who do not smoke. In contrast, caffeine inhibits CYP1A2 and increases both CLZ plasma 
concentrations and the risk of developing side effects linked to toxicity {{434 Odom-White,A. 1996; 
433 Hagg,S. 2000}}. Future studies incorporating these environmental factors may help identify 
more accurate predictors of response and develop dosage guides that are tailored to the individual 
patient. ADD SENTENCES ON STRESS  (Real et al, 2013) 
To conclude, we report no association between seven GRIN2B markers and CLZ response in our sample.  
Response to CLZ therapy is complex and likely to depend on multiple gene systems and environmental 
factors. Therefore, investigation of additional glutamate variants and variants within related 
neurotransmitter systems is warranted for future studies. Even though conclusive predictive markers 
remain elusive thus far, continued research to identify such markers remains of high interest to improve 
clinical response and treatment outcomes. 
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